Vectus Biosystems Limited (ASX:VBS)
0.1400
0.00 (0.00%)
Jan 30, 2026, 10:03 AM AEST
Vectus Biosystems Revenue
In the fiscal year ending June 30, 2025, Vectus Biosystems had annual revenue of 478.18K AUD, down -58.01%. Vectus Biosystems had revenue of 84.48K in the half year ending June 30, 2025, a decrease of -89.10%.
Revenue
478.18K
Revenue Growth
-58.01%
P/S Ratio
15.64
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.48M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 478.18K | -660.49K | -58.01% |
| Jun 30, 2024 | 1.14M | -215.86K | -15.94% |
| Jun 30, 2023 | 1.35M | 54.45K | 4.19% |
| Jun 30, 2022 | 1.30M | 282.09K | 27.71% |
| Jun 30, 2021 | 1.02M | 966.81K | 1,888.82% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 12.68M |
| Immuron | 7.29M |
| Biotron | 1.81M |
| Acrux | 1.19M |
| Anatara Lifesciences | 969.46K |
| InhaleRx | 833.90K |
| Patrys | 828.54K |
| AdAlta | 677.01K |